Any current/future new fundraising through debt or equity?

The transcript from the Q2FY25 earnings call of Shree Ganesh Remedies Limited does not mention any current or planned fundraising through debt or equity. No specific comments were made about raising capital for ongoing or future projects. Capex plans for expansion (blocks 9, 10, 11 at Ankleshwar and new blocks at Dahej) are contingent on project approvals and customer contracts but no financing details were discussed. The company is focusing on phased project developments, backed by existing resources and project-specific investments rather than broad fundraising. Management emphasizes organic

Any current/future capex/capital investment/strategic investment?

Blocks 9, 10, and 11 at Ankleshwar will be commissioned and designed only when specific projects or chemistry requirements arise; typical Capex per block ranges between ₹10-20 crore, totaling ₹50-80 crore for the three blocks. Block 7 at Dahej is being finalized; construction usually takes 15-18 months post-approval. Dahej site is planned for large-scale, dedicated customer projects with major Capex starting 1.5 to 2 years from now after signing supply contracts. Current capacity expansions at Ankleshwar and ongoing efforts aim to support scale-up and sample submissions before major Dahej inve

Future growth expectations in sales/revenue/volumes?

Revenue growth is expected driven by increasing CRAMS (Contract Research and Manufacturing Services) projects, with trial quantities being supplied and ramp-up over multiple quarters. Peak volumes for CRAMS projects are anticipated 1.5 to 2 years down the line, indicating gradual scale-up. New blocks (9,10,11) at Ankleshwar planned but will be commissioned based on confirmed projects; gross block addition estimated at Rs. 50-80 crores. Dahej site expansion is planned for commercial-scale production once supply contracts are signed; construction expected to take 15-18 months after groundwork. E

Future growth expectations in earnings/operating earnings/profits/EPS?

Growth expected to continue driven by strategic focus on product mix optimization and profitability enhancement (Page 4). Commercial supply for CRAMS projects ramping up over multiple quarters; peak volumes expected 1.5 to 2 years down the line (Pages 13-15). New blocks (9, 10, 11) and Dahej site expansions planned, contingent on project contracts, indicating capacity for future scale (Pages 13-14). EBITDA margins anticipated to normalize in the 24-28% range over the medium term; peak margin of 30%+ seen recently considered aberration due to initial CRAMS projects (Page 11). Revenue co

Current/ Expected Orderbook/ Pending Orders?

Currently engaged in multiple CRAMS projects with some commercialized, including one started in Q4 of last year. Trial quantities for ongoing CRAMS projects expected around Q2 of next financial year. Major revenue and volume ramp-up from these projects anticipated 1.5 to 2 years down the line. Customer is conducting market studies to clarify peak volume; clearer visibility expected by Q4 FY25. Additional CRAMS projects are in pipeline, with sample approvals and R&D ongoing. No specific orderbook numbers disclosed due to competitive reasons and NDAs. Blocks 9, 10, and 11 expansions planned post

Shree Ganesh Remedies LtdQ2 FY25Pharmaceuticals & Biotechnology

Shree Ganesh Remedies Ltd Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹639.75P/E: 53.2Market Cap: ₹822 CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

Revenue growth is expected driven by increasing CRAMS (Contract Research and Manufacturing Services) projects, with trial quantities being supplied and ramp-up over multiple quarters.
Peak volumes for CRAMS projects are anticipated 1.5 to 2 years down the line, indicating gradual scale-up.
New blocks (9,10,11) at Ankleshwar planned but will be commissioned based on confirmed projects; gross block addition estimated at Rs. 50-80 crores.
Dahej site expansion is planned for commercial-scale production once supply contracts are signed; construction expected to take 15-18 months after groundwork.
European market demand has been dampened recently but expected to stabilize with increased inquiries from multiple geographies including Europe, Japan, and USA.
Specialty chemicals and fine chemicals segments are showing promise with new inquiries and potential supplier upgrades.
Long-term projects indicate stable revenue streams 2-3 years ahead.
Overall margin guidance is 24-28% EBITDA, with higher margins in early CRAMS phases balancing out over time.

Margin guidance

Category 3

Growth expected to continue driven by strategic focus on product mix optimization and profitability enhancement (Page 4).
Commercial supply for CRAMS projects ramping up over multiple quarters; peak volumes expected 1.5 to 2 years down the line (Pages 13-15).
New blocks (9, 10, 11) and Dahej site expansions planned, contingent on project contracts, indicating capacity for future scale (Pages 13-14).
EBITDA margins anticipated to normalize in the 24-28% range over the medium term; peak margin of 30%+ seen recently considered aberration due to initial CRAMS projects (Page 11).
Revenue contribution from CRAMS projects expected to increase gradually but cautiously disclosed due to competitive reasons (Page 15).
Backward integration efforts aimed at maintaining healthy margins amid volume-driven pricing pressure (Page 7).
Overall, a steady revenue and margin growth trajectory is anticipated over 3-5 years with ongoing project commercialization and capacity expansion.

See what Shree Ganesh Remedies Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

The transcript from the Q2FY25 earnings call of Shree Ganesh Remedies Limited does not mention any current or planned fundraising through debt or equity.
No specific comments were made about raising capital for ongoing or future projects.
Capex plans for expansion (blocks 9, 10, 11 at Ankleshwar and new blocks at Dahej) are contingent on project approvals and customer contracts but no financing details were discussed.
The company is focusing on phased project developments, backed by existing resources and project-specific investments rather than broad fundraising.
Management emphasizes organic growth and capacity expansion based on customer demand without indicating external equity or debt issuance.

Order book

Currently engaged in multiple CRAMS projects with some commercialized, including one started in Q4 of last year.
Trial quantities for ongoing CRAMS projects expected around Q2 of next financial year.
Major revenue and volume ramp-up from these projects anticipated 1.5 to 2 years down the line.
Customer is conducting market studies to clarify peak volume; clearer visibility expected by Q4 FY25.
Additional CRAMS projects are in pipeline, with sample approvals and R&D ongoing.
No specific orderbook numbers disclosed due to competitive reasons and NDAs.
Blocks 9, 10, and 11 expansions planned post-project confirmation; gross block investment estimated between Rs. 50-80 crores.
Dahej site expansion contingent upon signed supply contracts for high-volume projects; commercial production expected after 1.5-2 years of sample approvals and construction.

See what Shree Ganesh Remedies Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Blocks 9, 10, and 11 at Ankleshwar will be commissioned and designed only when specific projects or chemistry requirements arise; typical Capex per block ranges between ₹10-20 crore, totaling ₹50-80 crore for the three blocks.
Block 7 at Dahej is being finalized; construction usually takes 15-18 months post-approval.
Dahej site is planned for large-scale, dedicated customer projects with major Capex starting 1.5 to 2 years from now after signing supply contracts.
Current capacity expansions at Ankleshwar and ongoing efforts aim to support scale-up and sample submissions before major Dahej investments.
The company employs a project-driven Capex approach, building capacity aligned with customer demand and technology.
Block 8 has started commercial operations from Q1 FY25 and is expected to contribute meaningfully soon.
Innovation efforts include backward integration and technology improvements to maintain margins and production efficiency.

Track Shree Ganesh Remedies Ltd — get its next earnings analysis in your feed

How does Shree Ganesh Remedies Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisShree Ganesh Remedies Ltd

Rev 3Mar 3

See where Shree Ganesh Remedies Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Shree Ganesh Remedies Ltd rank in Pharmaceuticals & Biotechnology?

Compare Shree Ganesh Remedies Ltd against every Pharmaceuticals & Biotechnology company (Q2 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Shree Ganesh Remedies Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Shree Ganesh Remedies Ltd Q2 FY25 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Shree Ganesh Remedies Ltd rank in Pharmaceuticals & Biotechnology?

Continue your research

What Shree Ganesh Remedies Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season